LB Pharmaceuticals (NASDAQ: LBRX) supplements prospectus after CMO transition
Rhea-AI Filing Summary
LB Pharmaceuticals Inc filed a prospectus supplement dated June 10, 2026 that incorporates a Form 8-K reporting the resignation of Chief Medical Officer Anna Eramo, M.D., effective June 15, 2026, and her transition to an adviser and consultant through September 15, 2026. The supplement describes a Separation and Consulting Agreement providing consulting services during a three-month Consulting Period, continuation of option vesting per company plans, reimbursement of COBRA healthcare premiums for up to 12 months, payment of base salary on a monthly basis through June 15, 2027, a prorated 100% target annual bonus for 2026, and acceleration such that 66,143 unvested option shares will vest and become exercisable on September 15, 2026. The company states Dr. Eramo’s departure is for personal reasons, is not related to clinical program operations or practices, and is not expected to have a material impact on clinical development activities or disclosed clinical milestones. The prospectus supplement updates the Registration Statement on Form S-1 (Registration No. 333-294900) and should be read with the Prospectus.
Positive
- None.
Negative
- None.
Insights
Separation terms are standard but include notable equity acceleration and extended pay.
The Separation Agreement accelerates vesting of 66,143 option shares to September 15, 2026 and provides continued base salary through June 15, 2027, plus a prorated 100% target bonus for 2026. The agreement also includes customary confidentiality and non‑disparagement covenants and a release of claims.
The company states the departure is for personal reasons and not related to clinical operations; timing and the consulting arrangement mean continuity of oversight is contractually supported. Subsequent filings or the company’s disclosures about a successor will clarify governance and operational continuity.
Clinical programs remain under existing teams while a replacement search is underway.
The company affirms that clinical development and operations teams will continue overseeing ongoing trials and that Dr. Eramo will provide full‑time consulting support through September 15, 2026. The filing states the departure "is not related to the Company’s clinical program operations or practices" and that no material impact on disclosed milestones is expected.
Operational risk depends on successor appointment and handover effectiveness; watch for subsequent disclosures naming a new CMO or providing milestone timing updates in future SEC reports or press releases.
Key Figures
Key Terms
Separation Agreement legal
acceleration of stock options financial
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did LB Pharmaceuticals (LBRX) disclose about its CMO transition?
What compensation and benefits does the Separation Agreement provide to Dr. Eramo?
Will LB Pharmaceuticals continue its clinical trials after the CMO change?
Does the prospectus supplement change the registration statement for the S-1?
Filed pursuant to Rule 424(b)(3)
Registration No. 333-294900
PROSPECTUS SUPPLEMENT
(To the Prospectus Dated April 14, 2026)
This prospectus supplement updates, amends and supplements the prospectus dated April 14, 2026 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-294900). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the prospectus.
This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 10, 2026, which is set forth below.
This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.
Our common stock is listed on The Nasdaq Global Market under the symbol “LBRX.” On June 9, 2026, the last reported sale price of our common stock was $29.27 per share.
Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 8 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.
Neither the Securities and Exchange Commission nor any other state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement is June 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 8, 2026
LB Pharmaceuticals Inc
(Exact name of registrant as specified in its charter)
| Delaware | 001-42831 | 81-1854347 | ||
| (state or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| One Pennsylvania Plaza, Suite 1025 New York, NY |
10119 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (212) 605-0300
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
| Common Stock, $0.0001 par value per share | LBRX | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. |
On June 16, 2026, Anna Eramo, M.D., for personal reasons will transition to a role of advisor to LB Pharmaceuticals Inc (the “Company”). On June 8, 2026, she resigned from her position as Chief Medical Officer of the Company effective June 15, 2026 (the “Separation Date”). She will continue to provide consulting services in a full-time capacity to the Company through September 15, 2026. Dr. Eramo’s departure is not related to the Company’s clinical program operations or practices, and the Company does not expect her departure to have a material impact on the Company’s clinical development activities or previously disclosed clinical milestones. A search is underway for her replacement, and the Company has experienced clinical development and operations teams who will continue to oversee the execution of the ongoing clinical trials.
In connection with her resignation, Dr. Eramo’s has entered into a separation and consulting agreement with the Company, dated as of June 8, 2026 (the “Separation Agreement”). Pursuant to the Separation Agreement, Dr. Eramo will provide consulting services to the Company for the three-month period following the Separation Date until September 15, 2026 (the “Consulting Period”). Pursuant to the Separation Agreement, if Dr. Eramo remains engaged as a consultant and complies with her obligations to the Company through the end of the Consulting Period, she will be entitled to (a) her current base salary on a monthly basis until June 15, 2027, (b) 100% of her target annual bonus for 2026 on a prorated basis, and (c) the acceleration of her outstanding stock options such that 66,143 of the unvested shares subject to the her stock options shall be vested and exercisable on September 15, 2026. Throughout the Consulting Period, Dr. Eramo’s existing options will continue to vest in accordance with the Company’s 2023 Stock Incentive Plan, 2025 Equity Incentive Plan and applicable grant agreements. In addition, the Company will provide Dr. Eramo with reimbursement of COBRA healthcare premium costs for the same level of coverage she had during employment until the earlier of (i) 12 months following the Separation Date, (ii) the expiration of Dr. Eramo’s eligibility for the continuation coverage, or (iii) the date Dr. Eramo becomes eligible for substantially equivalent healthcare coverage through another source. The Separation Agreement also contains confidentiality and non-disparagement covenants and a release of claims by Dr. Eramo.
The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Cautionary Statement Regarding Forward-Looking Statements
This Current Report on Form 8-K may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. These forward-looking statements include statements with respect to the impact of Dr. Eramo’s departure on the Company’s clinical development activities or previously disclosed clinical milestones, the Company’s ability to successfully find Dr. Eramo’s replacement, and the Company’s continuous execution of the ongoing clinical trials. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including risks and uncertainties related to the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company’s
business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Report on Form 10-Q for the quarters ended March 31, 2026 and in the Company’s other SEC filings. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
Description | |
| 10.1 | Separation and Consulting Agreement by and between LB Pharmaceuticals Inc and Anna Eramo, dated June 8, 2026. | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LB PHARMACEUTICALS INC | ||
| By: | /s/ Heather Turner | |
| Heather Turner Chief Executive Officer | ||
Dated: June 10, 2026